fludarabine has been researched along with n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K | 1 |
1 other study(ies) available for fludarabine and n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine
Article | Year |
---|---|
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine | 2009 |